Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· January 7, 2026
Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC
View original at finance.yahoo.comMerck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC Third Phase 3 trial in Merck’s KANDLELIT clinical development program, whic…
Ce que nous avons tiré de cette source
The claims Via News extracted from this document. We point to the source; we don't replace it.
KRAS is the most frequently mutated oncogene in cancer, and the KRAS G12C mutation occurs in approximately 4% to 14% of all patients with lung cancer globally
80% confidenceMerck operates the largest immuno-oncology clinical research program with over 1,600 trials across multiple cancers
80% confidenceCombination of oral calderasib with subcutaneous KEYTRUDA QLEX will evaluate whether this chemotherapy-free combination requiring no intravenous access may help improve outcomes for patients with KRAS G12C-mutant NSCLC
80% confidence
